Background
Genes encoding proteins involved in serotonergic metabolism are major candidates in association studies of mood disorders and suicidal behavior. This association study explores whether the tryptophan hydroxylase (TPH) gene, which codes for the rate-limiting enzyme of serotonin biosynthesis, is a susceptibility factor for manic-depressive illness, with or without a history of suicide attempts.
Methods
The TPH intron 7 A218C polymorphism was determined using a polymerase chain reaction–based method in DNA samples from 152 patients with bipolar disorder and 94 healthy control subjects.
Results
There was a significant association between TPH genotypes and manic-depressive illness. Among patients with bipolar disorder, no association was found between TPH alleles and suicidal behavior.
Conclusions
This result suggests the involvement of the TPH gene in susceptibility to manic-depressive illness. This preliminary result requires confirmation in further groups of patients and controls.
THERE IS compelling evidence that abnormalities of serotonergic neurotransmission contribute to depression. The major serotonin (5-hydroxytryptamine [5-HT]) metabolite is 5-hydroxyindoleacetic acid (5-HIAA), and its concentration is low in the cerebrospinal fluid of a subgroup of patients with unipolar depression who attempted suicide by violent means.1,2 Furthermore, platelet 5-HT uptake is diminished in patients with depression3 and especially in patients with bipolar disorder.4,5 Reduced binding of tritiated imipramine or tritiated paroxetine to brain 5-HT uptake sites and transporters has been found in patients with depression6 and in suicide victims.7
Low 5-HIAA levels in cerebrospinal fluid, indicating reduced serotonergic function, also are associated with impulsive behavior.8,9 In addition, among impulsive subjects, those with the lowest 5-HIAA concentrations have a history of suicide attempts.10
Although genetic factors have long been implicated in the etiopathogenesis of bipolar disorders11 and to a lesser extent in that of suicidal behavior,12-14 the mode of inheritance of manic-depressive illness and suicidal behavior is unclear.
The involvement of genetic factors in manic-depressive illness mostly has been investigated using linkage studies. Several chromosomal regions have been implicated, including 6pter-p24,15 13q13,15 15q11-qter,15 11p15,16 Xp27,17 Xq24-q27,18 the pericentromeric region of chromosome 18,19 and 21q22.3.20 However, subsequent studies have failed to confirm some of these positive results, possibly because of genetic heterogeneity and complex modes of inheritance of major affective disorders. Thus, nonparametric strategies, which do not require any knowledge of the genetic parameters underlying the disease, may be more appropriate for identifying genes involved in complex diseases. Recent association studies between candidate genes and manic-depressive illness suggest the implication of several genes of minor effect.21-24 Although stratification bias can cause false-positive results, case-control studies using polymorphic markers close to or within candidate genes may be an appropriate method for detecting genetic susceptibility factors. Thus, despite this bias, case-control analyses of complex diseases (eg, essential hypertension and Alzheimer disease) have proved to be useful.
Candidate genes implicated in 5-HT metabolism already have been tested for association with manic-depressive illness and suicidal behavior. Positive association between the monoamine oxidase A gene and manic-depressive illness have been reported.24 This followed the report of a point mutation in the monoamine oxidase A gene in affected males, belonging to a single pedigree, who showed borderline mental retardation, and violent behavior.25 Association between the 5-HT transporter gene and manic-depressive illness or suicide attempts remain controversial, because positive26 and negative results have been obtained.27,28 No association was found between 5-HT1A receptor gene and bipolar disorder.29
The rate-limiting enzyme of 5-HT synthesis—tryptophan hydroxylase (TPH)—is a candidate gene for bipolar disorder and suicidal behavior. Tryptophan hydroxylase catalyzes the oxygenation of tryptophan to 5-hydroxytryptophan, which is then decarboxylated to form 5-HT. The human gene for TPH has been cloned,30 and mapped on the short arm of chromosome 11 (11p14-p15.3).31 Two biallelic polymorphisms have been identified in intron 7: A218C and A779C, disclosed by restriction fragment length polymorphism analysis and by single-strand conformational polymorphism analysis, respectively.32 These 2 polymorphisms are in complete linkage disequilibrium in West European Caucasian controls.32 Two other polymorphisms were disclosed by AvaII and HinfI restriction enzymes, using the human TPH copy DNA probe C2-38, but have not been accurately mapped.30,33
In a group of Finnish violent offenders meeting criteria for alcohol abuse, Nielsen et al34 reported a significant difference in the conformational TPH polymorphism in intron 7 between subjects with and without a history of suicide attempts. In contrast, Abbar et al,33 using TPH C2-38/AvaII polymorphism, did not find any significant difference between patients who attempted suicide and normal control subjects. No association was found between patients with bipolar disorder and controls with TPH/AvaII in a preliminary case-control study.35
To further explore the involvement of the TPH gene, we studied the TPH A218C polymorphism in a new sample of patients with bipolar disorder, some with and some without a history of suicide attempts, and in controls.
After giving informed consent, 152 patients with bipolar disorder (103 patients with bipolar I disorder and 49 patients with bipolar II disorder) and 94 healthy volunteers were included in this study. Patients and controls were all French (at least 3 grandparents born in France). Patients with bipolar disorder (84 women and 68 men) were recruited from consecutive admissions to the psychiatric unit and controls (37 women and 57 men) were blood donors from Hôpital Pitié-Salpêtrière, Paris, France, and Hôpital Corentin Celton, Issy-les-Moulineaux, France.
Patients and controls were interviewed by trained psychiatrists (F.B. and M.L.) with a French version of the Diagnostic Interview for Genetic studies.36 Diagnosis with DSM-III-R,37 Research Diagnostic Criteria, and history of suicide attempts were assessed with this instrument. Demographic and clinical characteristics of patients with bipolar disorder and controls are given in Table 1.
To minimize morbidity among subjects in the control group, only blood donors older than 35 years were included. Controls with a personal or family history of mood disorders or suicide attempt disclosed by interview were excluded.
Suicide attempts were classified as violent or nonviolent according to the criteria proposed by Asberg et al.2 The criterion for suicide attempts was death intent requiring medical treatment at a hospital. Death intent and medical seriousness of the attempt were rated according to the 6-point scale of the Diagnostic Interview of Genetic Studies. Hanging attempts, use of firearms or knives, and jumping from heights were considered as violent attempts; drug overdoses were considered as nonviolent suicide attempts.
Because the 2 intron 7 TPH polymorphisms (A218C and A779C) are in complete disequilibrium,32 we tested A218C, which is more easily revealed. Twenty-milliliter edetic acid blood samples were collected, and DNA was prepared from lymphocyte pellets by sodium dodecyl sulfate lysis, proteinase K digestion, phenol and chlorophorm extraction, and ethanol precipitation and was resuspended in TRIS buffer and edetic acid. For genotyping, target sequences were amplified from 200 ng of genomic DNA using polymerase chain reaction (PCR) in a 50-µL reaction volume using a Hybaid cycler (MWG-Biotech GmbH, Ebersberg, Germany). The PCR primers were HTHSSCPA, 5′-TTC AGA TCC CTT CTA TAC CCC AGA-3′; and HTHSSCP5, 5′-GGA CAT GAC CTA AGA GTT CAT GGC A-3′; in 1.5-mmol/L magnesium chloride, 50 mmol of potassium chloride, 10 mmol of TRIS buffer, and 20 pmol of each oligonucleotide, 2 U of Taq DNA polymerase (Brunschwig, Basel, Switzerland) and 200 mmol of each dNTP per tube. The PCR program was as follows: first cycle for 3 minutes at 95°C, 30 seconds at 58°C, and 1 minute at 72°C; and 29 cycles for 1 minute at 92°C, 30 seconds at 58°C, and 1 minute at 72°C. After amplification, PCR products were digested with 8 U of BfaI (BioConcept, Allschwil, Switzerland) overnight, then electrophoresed on a 1.4% agarose gel (Brunschwig). DNA was visualized by ethidium bromide staining and UV transillumination. The uncut amplicon is 918 base pairs (bp) long. After digestion, the "A" allele gives 860-bp and 58 (not seen in the gel)-bp fragments, and the "C" allele gives 615-, 245-bp, and 58 (not seen in the gel)-bp fragments.
Allelic and genotypic distributions between patients and controls were compared using the χ2 test. Odds ratios and 95% confidence intervals were calculated using the Woolf's method. The Armitage linearity tendency test38 was used to identify any dose effect of a susceptibility allele. Differences were considered statistically significant at P=.05.
The TPH genotypic distributions were in Hardy-Weinberg equilibrium among patients (χ2=0.13, df=2; P=.93) and controls (χ2=0.08, df=2; P=.96). There was an association between TPH genotype and manic-depressive illness (Table 1) (χ2=12.23, df=2; P<.02). The allelic distributions for patients and controls were significantly different (χ2=12.00, df=1; P=.001). The frequency of the rare TPH A allele in the control group (0.37) was consistent with that previously described in West European Caucasian controls (0.36).32 The frequency of the A allele was higher in the patients with bipolar disorder (0.52). No difference between bipolar I and II disorder was found for A allele frequency (0.52 and 0.48, respectively). The odds ratio of bipolar disorder associated with 2 A alleles, at least 1 A allele, and 1 A allele only were 3.96 (95% confidence interval=1.76-8.94), 2.35 (95% confidence interval=1.34-4.12) and 1.96 (95% confidence interval=1.09-3.54), respectively.
No association was found between the TPH gene polymorphism (A218C) and suicidal behavior (presence vs absence of lifetime suicide attempt) in the patients with bipolar disorder. Among those who attempted suicide, no association was found for violent vs nonviolent suicide subgroups.
We report that a polymorphism in the intron 7 of the TPH gene is associated with manic-depressive illness. This finding seems to be robust, and discloses an effect that is consistent with a polygenic origin of bipolar disorder.
The risk of bipolar disorder is increased by the presence of at least 1 copy of the TPH A allele, and the risk is higher for TPH A–homozygous subjects. In our sample, there was a dose effect for the risk associated with the A allele for bipolar disorder as assessed by the linearity tendency test (χ2=12.19, df=1; P<.001).38
The allelic frequencies in our control population (Table 2) were similar to those reported by Nielsen et al32 in West European Caucasian control populations. Our sample of patients with bipolar disorder was recruited with the same geographical criteria as controls, ie, Caucasian and of French origin for at least 2 generations. Despite these precautions, there may have been a stratification bias, and replication is required in other samples of patients with bipolar disorder, using other nonparametric methods.
It is unclear how the TPH A allele acts as a risk factor for bipolar disorder. The A218C TPH polymorphism is located in a potential GATA transcription-factor binding site and therefore might affect TPH gene expression.32 Alternatively, this polymorphism may be nonfunctionally significant and our results may indicate only linkage disequilibrium between the TPH A allele and a different mutation in the TPH gene, or another nearby gene. Although the other TPH intron 7 polymorphism (A779C SSCP) is located upstream from the 3 acceptor splice site, it has no functional significance because no aberrant splice product from the TPH gene has been detected.32
We did not find any association between a previously studied small sample of patients with bipolar disorder (N=70) and another restriction fragment length polymorphism of the TPH gene (AvaII/C2-38).35 Because the location of the AvaII polymorphic site in the TPH locus is unknown, these discrepant results may be due to large distance between the 2 polymorphic sites (ie, the AvaII and the A218C polymorphism).
Possibly, a clinical or biological trait underlying manic-depressive illness could be associated with this TPH polymorphism. We, therefore, looked for an association between TPH polymorphism and suicide attempts. However, in our sample, there was no difference for A allele frequency between patients with bipolar disorder with and without a history of suicide attempts (0.56 and 0.48, respectively). This observation does not confirm the suggestion by Abbar et al33 that carrying the U allele (A779C polymorphism), which is in strong disequilibrium with the A allele (A218C polymorphism), protects against suicidal behavior in patients with bipolar disorder.
Furthermore, in our sample of patients who attempted suicide, no difference was found for the A allelic frequency between violent and nonviolent attempt subgroups (0.57 and 0.55, respectively). Nevertheless, this negative result could be due to lack of power because of the small sample size. Our sample of patients with bipolar disorder who have attempted suicide (14 violent and 38 nonviolent attempts) provides a power of less than 20% for detecting a difference between frequencies of 0.55 and 0.57 (unilateral test).
In summary, TPH intron 7 polymorphism seems to be associated with violent behavior without a history of suicide attempts34 and with manic-depressive illness. This TPH polymorphism might be associated with a trait related to violence and bipolar disorders rather than directly to these phenotypes themselves.
Accepted for publication January 6, 1997.
This research was supported by grant CRC 932208 from Assistance Publique, Institut National de la Santé et de la Recherche Médicale, Paris, France (Dr Bellivier) and grant 32-47315-96 from Fond National de la Recherche Suisse, Geneva, Switzerland.
We thank Jean-Louis Beaumont, MD, and his collaborators, as well as nurses Mireille Barré, Marie-Christine Benhouidga, Caroline Brachet, Nadine Gaudot, Marinette Naudier, Martine Platt, and Jean-Luc Thomas for technical assistance. We thank D. A. Nielsen, G. L. Jenkins, K. M. Stefanisco, K. K. Jefferson, and D. Goldman for providing their data before publication.
Reprints: Frank Bellivier, MD, Laboratoire de recherche sur les personnalités et conduites adaptatives, CNRS URA 1957 Pavillon Clérambault, Hôpital Pitié-Salpétrière, 47 boulevard de l'Hôpital, Paris 75013, France (e-mail: fbell@ext.jussieu.fr).
1.Van Praag
HKorf
JPuite
J 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid.
Nature. 1970;2251259- 1260
Google Scholar 2.Asberg
MTraksman
LThoren
P 5-HIAA in the cerebrospinal fluid: a biochemical suicide predictor.
Arch Gen Psychiatry. 1976;331193- 1197
Google Scholar 3.Tuomisto
JTukiainen
E Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients.
Nature. 1976;262596
Google Scholar 4.Scott
NReading
HLoundon
J Studies on human platelets in affective disorders.
Psychopharmacology. 1979;60131- 135
Google Scholar 5.Stahl
SWoo
DMefford
IBerger
PCiaranello
R Hyperserotonemia and platelet serotonin uptake in schizophrenia and affective disorders.
Am J Psychiatry. 1983;14026- 31
Google Scholar 6.Briley
MSLanger
SZRaiman
RSechter
DZarifian
E Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients.
Science. 1980;209303- 305
Google Scholar 7.Perry
EMarshall
EBlessed
GTomlinson
BPerry
R Decreased imipramine binding in brains of patients with depressive illness.
Br J Psychiatry. 1983;142188- 192
Google Scholar 8.Brown
GLGoodwin
FKBallenger
JCGoyer
PFJimerson
DCMajor
LF Aggression in humans correlates with cerebrospinal fluid amine metabolites.
Psychiatry Res. 1979;1131- 139
Google Scholar 9.Linnoila
MVirkkunen
MScheinin
MNuutila
ARimon
RGoodwin
FK Low cerebrospinal fluid 5-hydroxyindolacetic acid concentration differentiates impulsive from nonimpulsive violent behavior.
Life Sci. 1983;332609- 2614
Google Scholar 10.Linnoila
MVirkkunen
M Aggression, suicidality and serotonin.
J Clin Psychiatry. 1992;5346- 51
Google Scholar 11.Gershon
ES Genetics of manic-depressive illness. Goodwin
FKJamison
KReds
Manic-Depressive Illness. New York, NY Oxford University Press Inc1990;373- 399
Google Scholar 12.Wender
PKety
SRosenthal
D Psychiatric disorders in the biological and adopted families of adopted individuals with affective disorders.
Arch Gen Psychiatry. 1986;43923- 929
Google Scholar 13.Roy
ASegal
NLCenterwall
BSRobinette
CD Suicide in twins.
Arch Gen Psychiatry. 1991;4829- 32
Google Scholar 14.Egeland
JASussex
JN Suicide and family loading for affective disorders.
JAMA. 1985;254915- 918
Google Scholar 15.Ginns
EIOtt
JEgeland
JAAllen
CRFann
CSJPauls
DLWeissenbach
JCarulli
JPFalls
KMKeith
TPPaul
SM A genome-wide search for chromosomal loci linked to bipolar affective disorder in Old Order Amish.
Nat Genet. 1996;12431- 435
Google Scholar 16.Egeland
JAGerhard
DSPauls
DLSussex
JNKidd
KAllen
CRHostetter
AMHouseman
DE Bipolar affective disorders linked to DNA markers on chromosome 11.
Nature. 1987;325783- 787
Google Scholar 17.Baron
MRish
NHamburger
RMandell
BKuschner
SNewman
MDrumer
DBelmaker
R Genetic linkage between X chromosome markers and bipolar affective illness.
Nature. 1987;326289- 292
Google Scholar 18.Pekkarinen
PTerwilliger
JBredbacka
PEEnqvist
JPeltonen
L Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Genome Res. 1995;5105- 115
Google Scholar 19.Berettini
WFerraro
TGoldin
LWeeks
DDetera-Wadleigh
SNurnberger
JGershon
E Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene.
Proc Natl Acad Sci U S A. 1994;915918- 5921
Google Scholar 20.Straub
RELehner
TLuo
YLoth
EShao
WSharpe
LAlexander
JDas
KSimon
RFieve
RRLerer
BEndicott
JOtt
JGilliam
CBaron
M A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3.
Nat Genet. 1994;8291- 296
Google Scholar 21.Leboyer
MMalafosse
ABoularan
SCampion
DGheysen
FSamolyk
DHendrikson
BDenise
Edes Lauriers
ALpine
JPZarifian
EClerget-Darpoux
FMallet
J A tyrosine hydroxylase polymorphism reveals an association with manic-depressive illness.
Lancet. 1990;3351219
Google Scholar 22.Gill
MCastel
DHunt
NClements
ACham
PMurray
RM Tyrosine hydroxylase polymorphisms and bipolar affective disorder.
J Psychiatr Res. 1991;25179- 184
Google Scholar 23.Meloni
RLeboyer
MBellivier
FBarbe
BSamolyk
DAllilaire
JFMallet
J Association of manic-depressive illness with tyrosine hydroxylase microsatellite marker.
Lancet. 1995;345932
Google Scholar 24.Lim
LCCPowell
JFMurray
RGill
M Monoamine oxidase A gene and bipolar affective disorder.
Am J Hum Genet. 1994;541122- 1124
Google Scholar 25.Brunner
HGNelen
MBreakefield
XORopers
HHVan Oost
BA Abnormal behavior associated with a point mutation in the structural gene of monoamine oxydase A.
Science. 1993;262578- 580
Google Scholar 26.Collier
DAArranz
MJSham
PBattersby
SVallada
HGill
PAitchison
KJSodhi
MLi
TRoberts
GWSmith
BMorton
JMurray
RMSmith
DKirov
G The serotonin transporter is a potential susceptibility factor for bipolar affective disorder.
Neuroreport. 1996;71675- 1679
Google Scholar 27.Ogilvie
ADBattersby
SBudd
VJFink
GHarmar
AJGoodwin
GMDale Smith
CA Polymorphism in serotonin transporter gene associated with susceptibility to major depression.
Lancet. 1996;347731- 733
Google Scholar 28.Bellivier
FLaplanche
JLLeboyer
MFeingold
JBottos
CAllilaire
JFLaunay
JM Serotonin transporter gene polymorphisms and manic-depressive illness.
Biol Psychiatry. 1997;41750- 752
Google Scholar 29.Gutierrez
BArranz
MFnanas
LValls
VGuillamat
Rvan Os
JCollier
DA 5-HT
2A receptor gene and bipolar affective disorder.
Lancet. 1995;346969
Google Scholar 30.Boularan
SDarmon
MGanem
YLaunay
JMMallet
J Complete coding sequence of human tryptophan hydroxylase.
Nucleic Acids Res. 1990;184257
Google Scholar 31.Craig
SPBoularan
SDarmon
MMallet
JCraig
IW Localization of human tryptophan hydroxylase (TPH) to chromosome 11p15.3-p14 by in situ hybridization.
Cytogenet Cell Genet. 1991;56157- 159
Google Scholar 32.Nielsen
DAJenkins
GLStefanisco
KMJefferson
KKGoldman
D Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7.
Mol Brain Res. 1997;45145- 148
Google Scholar 33.Abbar
MCourtet
PAmadeo
SCaer
YMallet
JBaldy-Moulinier
MCastelnau
DMalafosse
A Suicidal behaviors and the tryptophan hydroxylase gene.
Arch Gen Psychiatry. 1995;52846- 849
Google Scholar 34.Nielsen
DAGoldman
DVirkkunen
MTokola
RRawlings
RLinnoila
M Suicidality and 5-hydroxyindolacetic acid concentration associated with a tryptophan hydroxylase polymorphism.
Arch Gen Psychiatry. 1994;5134- 38
Google Scholar 35.Malafosse
ALeboyer
MSabate
OLaklou
HAbbar
MAmadeo
SBoularan
SCampion
DCanceil
OCastelnau
DD'Amato
TGranger
BLoo
HPoirier
MFSavoye
CZarifian
EFeingold
JMallet
J Association and linkage studies of manic-depressive illness with two polymorphisms in the tryptophan hydroxylase gene.
Am J Psychiatry. 1977;1341123- 1126
Google Scholar 36.Nurnberger
JIBlehar
MCKaufman
CAYork-Cooler
CSimpson
SGHarkavy-Freedman
JSevere
JBMalaspina
DReich
T Diagnostic interview for genetic studies.
Arch Gen Psychiatry. 1994;51849- 864
Google Scholar 37.American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC American Psychiatric Association1987;
38.Armitage
PBerry
G Statistical Methods in Medical Research. Cambridge, Mass Blackwell Publishers1987;371- 407